Reply to issues raised in the Jansen/Reesink editorial.
作者信息
Silva Marcelo
出版信息
J Hepatol. 2007 Feb;46(2):350-1. doi: 10.1016/j.jhep.2006.11.003. Epub 2006 Nov 27.
PMID:17161883
Abstract
摘要
相似文献
1
Reply to issues raised in the Jansen/Reesink editorial.
J Hepatol. 2007 Feb;46(2):350-1. doi: 10.1016/j.jhep.2006.11.003. Epub 2006 Nov 27.
2
Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
J Hepatol. 2010 Sep;53(3):418-20. doi: 10.1016/j.jhep.2010.04.014. Epub 2010 May 31.
3
Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
J Hepatol. 2007 Feb;46(2):349; author reply 349-50. doi: 10.1016/j.jhep.2006.11.004. Epub 2006 Nov 27.
4
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505.
5
Peginterferon and ribavirin for chronic hepatitis C.
N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675.
6
Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
Hepatology. 2007 Dec;46(6):2048-9; author reply 2049-50. doi: 10.1002/hep.21798.
7
Peginterferon alfa-2a (Pegasys) for chronic hepatitis C.
Med Lett Drugs Ther. 2003 Mar 3;45(1151):19-20.
8
[Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med. 2005 Dec 15;147(51-52):69.
9
HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
Gastroenterology. 2007 Jun;132(7):2282-3. doi: 10.1053/j.gastro.2007.04.062.
10
Delaying HCV treatment in HIV-positive patients.
IAPAC Mon. 2005 May;11(5):147.
Zotero 插件